About Agenusbio
Agenusbio is a publicly listed company based in Lexington (United States) founded in 1994. The company has 316 employees. Agenusbio has completed 4 acquisitions, including 121 Bio, 4-Antibody and Aquilabio.com. Agenusbio offers products and services including Botensilimab. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity is Agenus Inc. Its competitors include AbbVie, Lilly and BeiGene; 1 of its 3 listed competitors has raised funding.
Company details
Developer of immunotherapies to treat cancer. The companys portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
- Headquarters Lexington, United States
- Employees 316
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website agenusbio.com
- Social LinkedIn X Facebook
- Legal Name Agenus Inc.
Products & Services of Agenusbio
Agenusbio offers a comprehensive portfolio of products and services, including Botensilimab.
CTLA-4 antibody enhancing immune response against tumors.
Funding Insights of Agenusbio
- Total Rounds 13
- First Round $10M
(Aug 2009)
- Investors Count 4
Latest 10 of 13 funding rounds of Agenusbio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | Post-IPO | – | – | ||
| Jul 2020 | $35M | Post-IPO | – | – | |
| Feb 2019 | $30M | Post-IPO | – | – | – |
| Oct 2018 | $40M | Post-IPO | – | – | – |
| Sep 2018 | $5M | Post-IPO | – | – | |
| Jan 2018 | $190M | Debt – Conventional | – | – | |
| Mar 2017 | $60M | Post-IPO | – | – | – |
| Dec 2015 | $7.4M | Post-IPO | – | – | – |
| Sep 2015 | $2.14M | Post-IPO | – | – | – |
| Mar 2015 | $21.14M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Agenusbio
Agenusbio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Incyte, Betta Pharmaceuticals and Zynext Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Zynext Ventures is focused on funding disruptive healthcare innovations. | zynextventures.com | Pennington, United States | ||
Healthcare royalty investments are focused on US and UK markets. | healthcareroyalty.com | Stamford, United States | ||
Therapeutics for treating cancer are developed by the company. | 2003 | bettapharma.com | Hangzhou, China | |
Small molecules are developed for cancer and skin disease treatments. | 1991 | incyte.com | Wilmington, United States |
Investor details for Agenusbio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Agenusbio
46 people are tracked at Agenusbio (26 in leadership, 9 in board & advisors, 11 in team); the tracked headcount is 316.
| Name | Role | Group |
|---|---|---|
Garo Armen | Chairman & CEO | Leadership |
Jennifer Buell | President & COO | Leadership |
Craig Winter | Chief Information Officer | Leadership |
Christine Klaskin | VP, Finance & Principal Financial & Accounting Officer | Leadership |
Robin Taylor | Chief Commercial Officer | Leadership |
Homa Yeganegi | Chief Product Strategy & Global Medical Affairs Officer | Leadership |
Tracy Mazza Clemente | Chief People Officer | Leadership |
Solomon Hall | Senior Director Of Information Technology | Leadership |
Austin Charette | Associate Director, Financial Reporting And Compliance | Leadership |
Harriett Shepherd (MCIPD) | Director HRBP | Leadership |
Ron Tetreault | Director Of CMC | Leadership |
Fery Pranadi | Associate Director, Global Supply Chain | Leadership |
Carol Haggerty-Koutsos | Senior Director Of Executive Administration | Leadership |
Doreene Burke | Head Of Global Supply Chain | Leadership |
Faith McKeone | Vp, Gma, Chief Of Staff | Leadership |
Jennifer Gray | Senior Director Facilities & EHS | Leadership |
Lauren O'Keefe | Director Human Resources Operations | Leadership |
Daniel Levey | Senior Director Vaccine Research | Leadership |
Steven O’Day | Chief Medical Officer | Leadership |
Frank Hermann M.D., Emba | Vice President Global Medical Affairs EMEA And Global Digital | Leadership |
26 more people are available in the full profile.
Complete people profiles for Agenusbio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Agenusbio
Agenusbio is a publicly listed company on the NASDAQ with ticker symbol AGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Feb 2000
- Listed onNASDAQ: AGEN
- Listed entityAgenus Inc.
- Exchange sectorHealth technology
- ISINUS00847G8042
- Share price$6.95 (-6.46% on the day) · 2026-10-13
- Market capitalisation$313.9M
- Price to earnings2.6
- EPS (diluted, trailing year)$2.65
- Volume (last session)995,561
Financials of Agenusbio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $114.2M | $115,000 | -$10.6M |
| 2024 | $103.5M | -$227.2M | -$111.1M |
| 2023 | $156.3M | -$245.8M | -$146.5M |
| 2022 | $98.0M | -$220.1M | -$173.3M |
| 2021 | $295.7M | -$23.9M | $44.0M |
Detailed financial statements for Agenusbio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Agenusbio
Agenusbio has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include 121 Bio, 4-Antibody and Aquilabio.com.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-based tools for protein modification and immunotherapies are developed. | 121bio.com | Boston, United States | 2013 | Jun 2016 | •••• | |
Developer of therapeutics cancer vaccines. | phosimmune.com | Charlottesville, United States | 2012 | Dec 2015 | $9.9M | |
Fully-human antibody discovery and optimization platform is utilized for therapeutics. | 4-antibody.com | Basel, Switzerland | 2002 | Jan 2014 | •••• | |
Human and animal healthcare products for immunological diseases are developed. | aquilabio.com | 2022 | Aug 2000 | •••• |
Complete acquisition details for Agenusbio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Agenusbio
8 dated milestones of Agenusbio across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Agenusbio is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Aquilabio.com.
- Funding First funding round of $10.0M.
- Acquisition Acquires 4-Antibody.
- Acquisition Acquires PhosImmune.
- Acquisition Acquires 121 Bio.
- Funding Latest funding round, Post-IPO,.
Competitors of Agenusbio
Agenusbio has 3 listed competitors in our database, 1 of them funded. They include AbbVie, Lilly and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abbvie.com | 2012 | Chicago, United States | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Agenusbio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Agenusbio
The website of Agenusbio (agenusbio.com) receives about 8.9K visits a month and ranks #3,213,430 among all websites worldwide, #4,223 in Biotechnology and Pharmaceuticals.
- Monthly visits8.9K
▲ 38.7% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,213,430
among all websites
- Category rank#4,223
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.6
- Average visit11 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Agenusbio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
antigenics.com | antigenics.com | 100% | – | ||
| anaptysbio.com | 79% | 10.8K | #1,418,623 | View details | |
neuralstem.com | neuralstem.com | 74% | – | ||
drugtargetreview.com | drugtargetreview.com | 44% | #387,873 | – | |
paozhen.net.cn | paozhen.net.cn | 44% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Agenusbio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Agenusbio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Agenusbio
Complete news archive for Agenusbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Agenusbio
Agenusbio was founded in 1994 and raised its 1st funding round 15 years after it was founded.
Agenusbio is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Agenusbio has 316 employees.
Annual revenue of Agenusbio is $114.2M as on Dec 31, 2025.
Developer of immunotherapies to treat cancer. The companys portfolio consists of bio-engineered therapies targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenusbio offers Botensilimab.
Yes, Agenusbio is publicly traded on NASDAQ under the ticker symbol AGEN.
Agenusbio has made 4 acquisitions, including 121 Bio, 4-Antibody, and Aquilabio.com.
Agenusbio has 4 investors. Key investors include Incyte, Betta Pharmaceuticals, Zynext Ventures, and HealthCare Royalty Partners.
Agenusbio operates through Agenus Inc..